Chornobai A. V., Chornobai M. A., Shlykova O. A., Izmailova O. V.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

Transforming growth factor β (TGF-β) is a bifunctional cytokine that inhibits (stimulates) the oncogenic progression of precancerous cells. Expression of TGF-β1 is associated with the progression and invasiveness of malignancies, including human gastrointestinal adenocarcinoma. The 869C allele of the TGF-β1 gene significantly increases the risk of gastric cardiac adenocarcinoma. The polymorphic variant T869C of the TGF-β1 gene was studied in 69 patients with gastric cancer and in 31 non-gastric cancer patients in the population of Poltava region. To determine polymorphic variant T869C gene TGF-β1 genomic DNA was isolated from peripheral venous blood. The T869C polymorphic region of the TGF-β1 gene was amplified by polymerase chain reaction (PCR) using specific oligonucleotide primers. Genotype frequencies were established in individuals without gastric cancer, which comprised TT – 0.323, CT – 0.548, CC – 0.129, and alleles T – 0.597, C – 0.403. In patients with gastric cancer, the frequency of genotypes and alleles of the TGF-β1 gene was not significantly different from individuals without development of gastric cancer: TT – 0.304, CT – 0.507, SS – 0.188%; T – 0,558%, C – 0,442. The calculated odds ratio for patients with СС genotype and patients with CT and TT genotype for patients with intestinal tumor type was 0.103, and for patients with diffuse tumor type 0.529 at HV = 5.16; 95% CI 1.39-19.09; χ2 = 5.235, p = 0.023. On the basis of the stage of tumor development and the age and sex of patients, the odds ratio with the T869C polymorphism genotypes of the TGF-β1 gene was not significant. According to the analysis of the obtained results, no significant differences were found between the frequencies of the T869C polymorphism genotypes of the TGF-β1 gene between patients with PC and the comparison group. It was also found that patients with gastric cancer who are carriers of the homozygous variant of the SS T869C polymorphism of the TGF-β1 gene develop a diffuse type of tumor with a more unfavorable course of the disease.

gastric cancer, transforming growth factor, T869C polymorphism of TGF-β1 gene.

1. Macias MJ, Martin-Malpartida P, Massague J. Structural determinants of Smad function in TGF-b signaling. Trends in Biochemical Sciences. 2015;40(6):296-8.
2. Robertson IB, Rifkin DB. Unchaining the beast; insights from structural and evolutionary studies on TGFβ secretion, sequestration, and activation. Cytokine Growth Factor Rev. 2013;24:355-72.
3. Averbakh MM, Panova LV, Hubkyna MF, Horelova LA. Soderzhanye YL-21 y transformyruiushcheho faktora rosta – β (TGF-β) v syvorotke detei y podrostkov, bolnykh razlychnymy formamy lehochnoho tuberkuleza. International journal of applied and fundamental research. 2015;5:42- 5. [in Russiаn].
4. Robson H, Anderson E, James RD, Schofield PF. Transforming growth factor beta 1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients. British Journal of Cancer. 2006;74:753.
5. Marı´a Asuncio´n Garcı´a-Gonza´lez, David Nicola´ s-Pe´rez, Angel Lanas. Prognostic Role of Host Cyclooxygenase and Cytokine Genotypes in a Caucasian Cohort of Patients with Gastric Adenocarcinoma. Plos One. 2012;7:11.
6. Shevchenko VE, Briukhovetskyi YS, Nykyforova NZ. Transformyruiushchyi faktor rosta beta-1 v onkoheneze adenokartsynomy lehkoho cheloveka. Uspekhy molekuliarnoi onkolohyy. 2017;3:67-4. [in Russiаn].
7. Babishkyna NN, Vtorushyn SV, Dronova TA, Krakhmal NV, Zavialova MV, Cherdyntseva NV. Rol retseptora transformyruiushcheho faktora rosta βI v prohressyrovanyy liumynalnoho podtypa raka molochnoi zhelezy. Sybyrskyi onkolohycheskyi zhurnal. 2017;2:27-5. [in Russiаn].
8. Maehara Y, Kakej Y, Kabashima A. Role of transforming growth factor-beta 1 in invasion and metastasis in gastric carcinoma. J. Clin. Oncol. 1999;l(17):607-14.
9. Hawinkels LJ, Verspaget HW, van Duijn WBr. Tissue level, activation and cellular localisation of TGF-beta1 and association with survival in gastric cancer patients. J. Cancer. 2007;l(97):398-404.
10. Mahajan R, El-Omar EM, Lissowska J. Genetic Variants in T Helper Cell Type 1, 2 and 3 Pathways and Gastric Cancer Risk in a Polish Population. Jpn J Clin Oncol. 2008;38(9):626-33.
11. Zhou Y, Jin GF, Jiang GJ. Correlations of polymorphisms of TGF-B1 and TGF-BR2 genes to genetic susceptibility to gastric cancer. 2007;26(6):581-5.
12. Martelossi Cebinelli GC, Paiva Trugilo K, Badaró Garcia S, Brajão de Oliveira K. TGF-β1 functional polymorphisms: a review. European Cytokine Network. 2016;27(4):81-9.
13. Jin G, Wang L, Chen W. Variant alleles of TGFB1 and TGFBR2 are associated with a decreased risk of gastric cancer in a Chinese population. Int J Cancer. 2007;120(6):1330-5.
14. Lixia Xu, Zhirong Zeng, Bin Chen. Association between the TGFB1-509C/T and TGFBR2-875A/G polymorphisms and gastric cancer: a casecontrol study. Oncol Lett. 2011;2(2):371-7.
15. Guo W, Dong Z, GuoY. Polymorphisms of transforming growth factor-b1 associated with increased risk of gastric cardia adenocarcinoma in north China. International journal of immunogenetics. 2011;38:215-24.
16. Maehara Y, Kakeji Y, Kabashima A, Emi Y, Watanabe A. Role of transforming growth factor-beta 1 in invasion and metastasis in gastric carcinoma. J Clin Oncol. 1999;17:607-14.
17. Hawinkels LJ, Verspaget HW, van Duijn W, van der Zon JM, Zuidwijk K. Tissue level, activation and cellular localisation of TGF-beta1 and association with survival in gastric cancer patients. Br J Cancer. 2007;97:398-404.
18. Wang KS, Hu ZL, Li JH, Xiao DS, Wen JF. Enhancement of metastatic and invasive capacity of gastric cancer cells by transforming growth factorbeta1. Acta Biochim Biophys Sin (Shanghai). 2006;38:179-86.

«Bulletin of problems biology and medicine» Issue 3 (152), 2019 year, 214-218 pages, index UDK 575.174.015.3:618.19-006.6-02

10.29254/2077-4214-2019-3-152-214-218